RANK ligand and the regulation of skeletal remodeling

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1120-1122

  Bell, Norman H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROSTAGLANDIN E2; PROTEIN RANK; RALOXIFENE; RECEPTOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

BONE MARROW CELL; BONE REMODELING; BREAST CANCER; CANCER RISK; CELL ACTIVATION; CELL DIFFERENTIATION; CORONARY ARTERY DISEASE; ESTROGEN DEFICIENCY; GENE MUTATION; HUMAN; MUTATION; NONHUMAN; NOTE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIDE EFFECT; STROKE;

EID: 0037399235     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI18358     Document Type: Note

References (24)

1. Riggs, B.L., Khosla, S., and Melton, L.J. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302.
2. Pacifici, R. 1996. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11:1043-1051.
3. Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137.
4. Suda, T., et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357.
5. Duong, L.T., and Rodan, G.A. 2001. Regulation of osteoclast formation and function. Rev. Endocr. Metab. Disord. 2:95-104.
6. Tanaka, S., et al. 1993. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263.
7. Strivastava, S., et al. 2001. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276:8836-8840.
8. Hofbauer, L.C., et al. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15:2-12.
9. Finkelman, R.D., Bell, N.H., Strong, D.D., Demers, L.M., and Baylink, D.J. 1992. Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss. Proc. Natl. Acad. Sci. U. S. A. 89:12190-12193.
10. Thirunavukkarasu, K.T., et al. 2001. Stimulation of osceoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-β). J. Biol. Chem. 276:36241-36250.
11. Weitzmann, M.N., et al. 2000. B lymphocytes inhibit human osteoclastogenesis by secretion of TGFβ. J. Cell. Biochem. 78:318-324.
12. Eghbali-Fatourechi, G., et al. 2003. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111:1221-1230. doi:10.1172/JCI200317215.
13. Bucay, N., et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-1268.
14. Whyte, M.P., et al. 2002. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347:175-184.
15. Cundy, T., et al. 2002. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11:2119-2127.
16. Johnson-Pais, T.L., et al. 2002. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J. Bone Miner. Res. 18:376-380.
17. Whyte, M.P., and Hughes, A.E. 2002. Expansile skeletal hyperphospharasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner. Res. 18:376-380.
18. Min, H., et al. 2000. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med. 192:463-474.
19. Rodan, G.A., and Martin, T.J. 2000. Therapeutic approaches to bone diseases. Science. 289:1508-1514
20. Nelson, H.D., Humphrey, L.L., Nygren, P., Teutsch, S.M., and Allan, J.D. 2002. Post-menopausal hormone replacement therapy: scientific review. JAMA. 288:872-881.
21. Ott, S.M.,Oleksik, A., Lu, Y., Harper, K., and Lips, P. 2002. Bone histomorphometric and biochemical markers: results of a 2-year placebo-controlled trial of raloxifene in post-menopausal women. J. Bone Miner. Res. 17:341-348.
22. Mashiba, T., et al. 2001. Effect of suppressed bone turnover by bisphosphonate on microdamage and biomechanical properties in clinically relevant skeletal sires in beagles. Bone. 28:524-531.
23. Bekker, P.J., et al. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16:348-360.
24. Body, J.J., et al. 2003. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 97(Suppl. 3):887-892.